The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 45 results
Sort by date: Descending
Encores: Not included
Bipolar Disorder
Schizophrenia
USPC 2025 POSTER
Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD6

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
Bipolar Disorder
USPC 2025 POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Craig Chepke, MD,4 Andrew J. Cutler, MD5,6 

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
USPC 2025 POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,2 Craig Chepke, MD,5 Rakesh Jain, MD6 

View poster
Listen to Audio Abstract
0:00 0:00
Schizophrenia
Sleep-wake disorders
World Sleep 2025 PRESENTATION
Vibrance-1: A Randomized Phase 2 Study Evaluating Safety and Efficacy of the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680) in Patients with Narcolepsy Type 1
AUTHOR(S)

Presented by Giuseppe Plazzi

View presentation
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
World Sleep 2025 PRESENTATION
Improvement in the Severity of Narcolepsy Symptoms and Fatigue in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
AUTHOR(S)

Presented by Yves Dauvilliers

View presentation
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
World Sleep 2025 PRESENTATION
Improvement in Patient-reported Cognitive Functioning in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
AUTHOR(S)

Presented by Giuseppe Plazzi

View presentation
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders